| " Cytokinergic" IgE clone SPE-7 contains functional IgG-IgE complexes M Sypka, M Zwicker, AC Uldry, MF Bachmann, M Vogel, P Engeroff SWISS MEDICAL WEEKLY 153, 22S-22S, 2023 | | 2023 |
| 14. Tagung Schweine-und Geflügelernährung, Tagungsband, 21.-23. November 2017, Lutherstadt Wittenberg, Martin-Luther-Universität Halle-Wittenberg A Zeyner, H Kluth, M Bulang, M Bochnia, M Bachmann Martin-Luther-Universität Halle-Wittenberg, Institut für Agrar-und …, 2017 | | 2017 |
| 5.1 Sustained inflammasome activation by BCG is crucially dependent on the engagement of the appropriate TLR signalling pathway D Mohanan, F Zabel, P Johansen, P Sander, TM Kündig, MF Bachmann TARGETTING INNATE IMMUNE RESPONSES TO IMPROVE VACCINE STRATEGIES, 37, 2013 | | 2013 |
| 6 Tuning the Immune Response to Our Advantage: Design of Vaccines with Tailored Functions TA Röhn, MF Bachmann MEDICINAL PROTEIN ENGINEERING, 0 | | |
| A composition comprising a virus-like particle and at least ghrelin or a ghrelin-derived peptide bound thereto MF Bachmann, A Fulurija | | 2007 |
| A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy G Senti, C Bull, P Mueller, M Ulrich, M Bachmann, W Renner, T Kuendig ALLERGY 62, 2007 | | 2007 |
| A double-blind, placebo-controlled phase Ila study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy T Kuendig, C Pichler, K Scherer, A Bircher, P Mueller, M Ulrich, ... ALLERGY 62, 2007 | | 2007 |
| A high-throughput alphavirus-based expression cloning system for mammalian cells D Koller, C Ruedl, M Loetscher, J Vlach, S Oehen, K Oertle, M Schirinzi, ... Nature biotechnology 19 (9), 851-855, 2001 | 36 | 2001 |
| A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses A Jegerlehner, A Tissot, F Lechner, P Sebbel, I Erdmann, T Kündig, ... Vaccine 20 (25-26), 3104-3112, 2002 | 329 | 2002 |
| A multi-target nanovaccine confers anti-tumor efficacy against head & neck carcinoma R Josi, M Farjia, M Vogel, M Bachmann, MO Mohsen SWISS MEDICAL WEEKLY 152, 13S-13S, 2022 | | 2022 |
| A new drug-modifying therapy for Type 2 Diabetes Mellitus ES Roesti, CN Boyle, DT Meier, M Sande-Melon, M Vogel, MF Bachmann SWISS MEDICAL WEEKLY, 27S-27S, 2019 | | 2019 |
| A novel double mosaic virus-like particle-based vaccine against SARS-CoV-2 incorporates both receptor binding motif (RBM) and fusion domain X Chang, A Zeltins, MO Mohsen, Z Gharailoo, L Zha, X Liu, S Walton, ... Vaccines 9 (11), 1287, 2021 | 13 | 2021 |
| A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. Vaccines 2021, 9, 1287 X Chang, A Zeltins, MO Mohsen, Z Gharailoo, L Zha, X Liu, S Walton, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| A novel mechanism of IgE regulation by IgE-allergen complexes via CD23 P Engeroff, K Plattner, F Thoms, M Bachmann, M Vogel World Allergy Organization Journal 13 (8), 2020 | | 2020 |
| A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation P Engeroff, M Fellmann, D Yerly, MF Bachmann, M Vogel Journal of Allergy and Clinical Immunology 142 (2), 557-568. e6, 2018 | 28 | 2018 |
| A novel virus-like particle for the treatment of cat allergy P Krenger, MD Heath, TC Velazquez, MF Kramer, A Zeltins, ... CLINICAL AND EXPERIMENTAL ALLERGY 52 (8), 1034-1035, 2022 | | 2022 |
| A novel virus-like particle platform for the treatment of peanut allergy: mechanistic insights P Krenger, J Sobczak, M Heath, M Skinner, M Kramer, A Zeltins, ... SWISS MEDICAL WEEKLY 152, 14S-14S, 2022 | | 2022 |
| A novel VLP-based glycoengineered vaccine against Actinobacillus pleuropneumoniae J Sobczak, S Roongta, T Keys, V Lentsch, I Balke, A Zeltins, M Vogel, ... SWISS MEDICAL WEEKLY 152, 32S-32S, 2022 | | 2022 |
| A Randomized, Double-Blinded, Placebo-Controlled, Phase I Trial to Determine the Safety and Induction of Antibody Response of an Interleukin-1beta Vaccine in Type 2 Diabetic … C Cavelti-Weder, K Timper, E Seelig, C Keller, M Osranek, U Laessing, ... DIABETES 64, A282-A282, 2015 | | 2015 |
| A scalable and highly immunogenic viruslike particlebased vaccine against SARSCoV2 MO Mohsen, I Balke, S Zinkhan, V Zeltina, X Liu, X Chang, PS Krenger, ... Allergy 77 (1), 243-257, 2022 | 38 | 2022 |
